Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.3.1.108 (TAT)
 2,389 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thyroid autoantibodies and thyroid function were studied in 175 patients with rheumatoid arthritis (ARA criteria, 1987). The study included 149 women and 26 men aged (54.7 +/- 13.1) all treated in the Clinic of Rheumatology, Higher Medical Institute, Plovdiv. A control group comprising 72 healthy subjects (aged 51.2 +/- 3.2) was used. Rheumatoid factor (RF) (latex agglutination test and Waaler-Rose test), antithyroglobulin (TAT) and antimicrosomal antibodies (MAT), thyroid stimulating hormone (TSH) and the free fraction of thyroxine (FT4) were measured. 69.7% of all patients tested positive for RF by the latex test and 64.5% by the Waaler-Rose test. TAT was found in 55 (31.4%), MAT in 26 (14.8%) from all the examined, which is significantly greater in comparison with the controls (p < 0.05). The thyroid gland was in a euthyroid state in most of the RA patients although MAT and/or TAT were detected in them. The results suggest existence of two autoimmune diseases - rheumatoid arthritis and Hashimoto's thyroiditis and raise the question of whether they are not manifestations of a single autoimmune disease with different body organ localisation.
 ...
PMID:Immune profile and thyroid function in patients with rheumatoid arthritis. 1535 11

Primary hyperparathyroidism (PHP; serum calcium 2.75 mmol/L, PTH 226 pg/ml) had been the first clinical manifestation of MEN-2A in a female patient (aged 55 years) with a mutation (Y791F, TAT-->TTT) in exon 13 of the RET proto-oncogene. The patient has a pentagastrin-induced rise in serum calcitonin (up to 57 pg/ml) considered normal for noncarriers but abnormal in family members of MEN-2 patients. This is the first case of MEN-2 due to this specific mutation with primary hyperparathyroidism as the first manifestation of the disease. In addition, the patient harbored, within the Menin gene, a polymorphism (D418D) reportedly associated with sporadic primary hyperparathyroidism. This case report indicates that molecular biological tests in MEN- 2 may only suggest a certain phenotype but cannot predict it with certainty. It may also suggest that genetic screening for MEN-2 may be advisable in patients with primary hyperparathyroidism and a borderline-high pentagastrin stimulation test, even in the absence of a positive family history.
Thyroid 2005 Nov
PMID:Primary hyperparathyroidism as the leading symptom in a patient with a Y791F RET mutation. 1635 97